September 29, 2022
4D pharma will not report it’s half year interim results
4D pharma will not report its interim results for the 6 months to 30 June 2022 by 30 September as…
September 29, 2022
4D pharma will not report it’s half year interim results
4D pharma will not report its interim results for the 6 months to 30 June 2022 by 30 September as required by Rule 18 of the AIM Rules for Companies,...
ProBiotix Health with new CEO
June 14, 2022
FDA Approves BMS’s Camzyos for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM)
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment...
GSK’s Daprodustat Receives FDA Filing Acceptance
April 20, 2022
Allergan’s BOTOX Cosmetic Celebrates 20th Birthday
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating 20th anniversary of FDA's approval of Botox Cosmetic.
EMA and the EUnetHTA 21 consortium set priorities for their collaboration
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a joint work plan until 2023....
Sanofi Launches First-In-Pharma Diversity, Equity & Inclusion Board
Sanofi has launched its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors....
